Tags

Type your tag names separated by a space and hit enter

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein.
Virus Res. 2014 Dec 19; 194:200-10.VR

Abstract

The recent outbreak of Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) infection has led to more than 800 laboratory-confirmed MERS cases with a high case fatality rate (∼35%), posing a serious threat to global public health and calling for the development of effective and safe therapeutic and prophylactic strategies to treat and prevent MERS-CoV infection. Here we discuss the most recent studies on the structure of the MERS-CoV spike protein and its role in virus binding and entry, and the development of MERS-CoV entry/fusion inhibitors targeting the S1 subunit, particularly the receptor-binding domain (RBD), and the S2 subunit, especially the HR1 region, of the MERS-CoV spike protein. We then look ahead to future applications of these viral entry/fusion inhibitors, either alone or in combination with specific and nonspecific MERS-CoV replication inhibitors, for the treatment and prevention of MERS-CoV infection.

Authors+Show Affiliations

Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Xuhui District, Shanghai 200032, China.Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Xuhui District, Shanghai 200032, China; Department of Medical Microbiology and Immunology, School of Basic Medicine, Dali University, Dali 671000, China.Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Xuhui District, Shanghai 200032, China.Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Xuhui District, Shanghai 200032, China.Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Xuhui District, Shanghai 200032, China.Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Xuhui District, Shanghai 200032, China.Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Xuhui District, Shanghai 200032, China. Electronic address: lul@fudan.edu.cn.Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Road, Xuhui District, Shanghai 200032, China; Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA. Electronic address: shibojiang@fudan.edu.cn.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25451066

Citation

Xia, Shuai, et al. "Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Entry Inhibitors Targeting Spike Protein." Virus Research, vol. 194, 2014, pp. 200-10.
Xia S, Liu Q, Wang Q, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014;194:200-10.
Xia, S., Liu, Q., Wang, Q., Sun, Z., Su, S., Du, L., Ying, T., Lu, L., & Jiang, S. (2014). Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Research, 194, 200-10. https://doi.org/10.1016/j.virusres.2014.10.007
Xia S, et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Entry Inhibitors Targeting Spike Protein. Virus Res. 2014 Dec 19;194:200-10. PubMed PMID: 25451066.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. AU - Xia,Shuai, AU - Liu,Qi, AU - Wang,Qian, AU - Sun,Zhiwu, AU - Su,Shan, AU - Du,Lanying, AU - Ying,Tianlei, AU - Lu,Lu, AU - Jiang,Shibo, Y1 - 2014/10/14/ PY - 2014/08/15/received PY - 2014/10/06/revised PY - 2014/10/06/accepted PY - 2014/12/3/entrez PY - 2014/12/3/pubmed PY - 2015/7/18/medline KW - Entry inhibitor KW - Fusion inhibitor KW - MERS-CoV KW - Middle East respiratory syndrome coronavirus KW - Receptor-binding domain KW - Six-helix bundle SP - 200 EP - 10 JF - Virus research JO - Virus Res. VL - 194 N2 - The recent outbreak of Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) infection has led to more than 800 laboratory-confirmed MERS cases with a high case fatality rate (∼35%), posing a serious threat to global public health and calling for the development of effective and safe therapeutic and prophylactic strategies to treat and prevent MERS-CoV infection. Here we discuss the most recent studies on the structure of the MERS-CoV spike protein and its role in virus binding and entry, and the development of MERS-CoV entry/fusion inhibitors targeting the S1 subunit, particularly the receptor-binding domain (RBD), and the S2 subunit, especially the HR1 region, of the MERS-CoV spike protein. We then look ahead to future applications of these viral entry/fusion inhibitors, either alone or in combination with specific and nonspecific MERS-CoV replication inhibitors, for the treatment and prevention of MERS-CoV infection. SN - 1872-7492 UR - https://www.unboundmedicine.com/medline/citation/25451066/Middle_East_respiratory_syndrome_coronavirus__MERS_CoV__entry_inhibitors_targeting_spike_protein_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-1702(14)00412-2 DB - PRIME DP - Unbound Medicine ER -